Related Experiment Video
Updated: Jun 3, 2026
10:32
Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
Published on: June 17, 2013
Mice lacking major brain gangliosides develop parkinsonism.
Gusheng Wu1, Zi-Hua Lu, Neil Kulkarni
1Department of Neurology and Neurosciences, New Jersey Medical School, UMDNJ, 185 So. Orange Ave., MSB-H506, Newark, NJ 07103, USA. ledeenro@umdnj.edu
Neurochemical Research
|March 15, 2011
Summary
Brain ganglioside GM1 abnormality may contribute to Parkinson's disease (PD) pathology. Restoring GM1 levels in genetically modified mice with PD symptoms improved motor function and reduced key disease markers.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Parkinson's disease (PD) is a prevalent neurodegenerative disorder with unmet needs for disease-modifying treatments.
- Understanding the underlying pathophysiology is crucial for developing effective therapies.
- Brain ganglioside abnormalities, specifically GM1, are implicated in neurodegenerative processes.
Purpose of the Study:
- To investigate the role of brain ganglioside GM1 in Parkinson's disease pathogenesis.
- To explore the therapeutic potential of GM1-related interventions.
Main Methods:
- Utilized genetically engineered mice lacking GM2/GD2 synthase (Galgt1 knockout) to create a model of ganglioside depletion.
- Assessed motor function, dopamine levels, dopaminergic neuron integrity, and alpha-synuclein aggregation in knockout mice.
- Administered L-DOPA and LIGA-20 (a GM1 analog) to evaluate their effects on parkinsonian symptoms.
Main Results:
- Galgt1 knockout mice exhibited motor disabilities, dopamine depletion, loss of substantia nigra neurons, and alpha-synuclein aggregation, mimicking PD.
- L-DOPA administration ameliorated motor deficits in these mice.
- Treatment with LIGA-20 significantly attenuated parkinsonism manifestations, suggesting a neuroprotective role of GM1.
Conclusions:
- Perturbation of intracellular GM1 mechanisms may be a contributing factor in Parkinson's disease.
- Restoring GM1 levels holds therapeutic promise for PD treatment.
- This study highlights gangliosides as potential targets for novel PD therapies.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...